EYC-0305 in Neovascular (Wet) AMD: First-in-Patients Safety and Tolerability Study

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1b/2a trial evaluates the safety, tolerability, pharmacokinetics, and immunogenicity of intravitreal EYC-0305 administered every 24 weeks in adults with neovascular AMD. It also examines how the drug affects disease activity and vision over time. The study collects PK data and safety information to guide future development. Participants will undergo regular eye exams and imaging to monitor response and adverse events. Primary goals focus on safety in early-dose cohorts, with exploratory signals of efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria
* Willing and able to comply with clinic visits and study-related procedures
* Provide signed informed consent

Exclusion Criteria:

* Known hypersensitivity or known allergy that would preclude study drug administration
* Inability to obtain ophthalmic imaging, eg, due to media opacity, inadequate pupillary dilation, allergy to fluorescein dye or lack of venous access
* Uncontrolled diabetes mellitus
* History of cerebrovascular accident (CVA) or myocardial infarction within 180 days of the Day 1 visit
* Renal failure, dialysis, or history of renal transplant
* Concurrent psychiatric or medical condition that in the opinion of the Investigator will interfere with study participation or completion
* Pregnant or breastfeeding women

Where it's running

• Beverly Hills, CA
  Beverly Hills, California, United States Recruiting
• Modesto, CA
  Modesto, California, United States Recruiting
• Wake Forest, NC
  Wake Forest, North Carolina, United States Recruiting
• Erie, PA
  Erie, Pennsylvania, United States Recruiting
• Bellaire, TX
  Bellaire, Texas, United States Recruiting
• McAllen, TX
  McAllen, Texas, United States Recruiting

Study contacts

• Study coordinator: Kim Reed, OD, FAAO
• Email: info@eyconis.com
• Phone: 1-866-392-6647

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AIV007 Periocular Shot for Wet AMD

  This trial tests whether a periocular injection of AIV007 can improve vision and safety in people with wet age-related macular degeneration, compared with the standard Eylea injections.

  Recruiting at 2 sites Phase 2 AiViva BioPharma, Inc. · Torrance, California and 1 other locations · NCT07557121

• Long-term follow-up for patients with wet age-related macular degeneration receiving SKG0106

  This study is testing how well and safely the treatment SKG0106 works for people with wet age-related macular degeneration over a long period after their last injection.

  Recruiting at 2 sites Skyline Therapeutics · Boston, Massachusetts and 9 other locations · NCT06346600

• Treatment for wet age-related macular degeneration using 4D-150

  This study is testing a new gene therapy called 4D-150 to see if it can improve vision in adults with wet age-related macular degeneration who are already receiving other treatments.

  Recruiting at 21 sites Phase 1/2 4D Molecular Therapeutics · Phoenix, Arizona and 25 other locations · NCT05197270

• JWK001 subretinal therapy for neovascular AMD

  This study tests a single subretinal dose of JWK001 at different levels in people with wet age-related macular degeneration who have previously responded to anti-VEGF treatment.

  Recruiting at 2 sites Phase 2 West China Hospital · Beijing, Beijing Municipality and 15 other locations · NCT07776522

• Ixo-vec Contralateral Dosing in Bilateral Wet AMD

  Researchers are testing whether giving Ixo-vec to the second eye of adults with bilateral wet AMD is safe and helps vision over time.

  Recruiting at 12 sites Phase 2 Adverum Biotechnologies, Inc. · Phoenix, Arizona and 11 other locations · NCT07630649

• Using OCT Angiography to Diagnose and Evaluate Wet AMD

  This study is testing if a special imaging technique can help doctors find new blood vessels in older adults with wet age-related macular degeneration and see how blood flow might affect the condition.

  Recruiting Oregon Health and Science University · Portland, Oregon · NCT02253030

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.